Understand the source comparison
SS-LUP-332 Exercise Mimetic Complete Guide 2026: Comparison With Other Metabolic Modulators
SLU-PP-332 REV-ERB agonist. Activates AMPK, mitochondrial biogenesis Improved glucose clearance, fat oxidation, mitochondrial density Preclinical only (rodent models) Subcutaneous injection Strongest metabolic mimetic evidence for AMPK activation without CNS s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SLU-PP-332
- REV-ERB agonist. Activates AMPK, mitochondrial biogenesis
- Improved glucose clearance, fat oxidation, mitochondrial density
- Preclinical only (rodent models)
- Subcutaneous injection
- Strongest metabolic mimetic evidence for AMPK activation without CNS stimulation. No human data limits application
- AICAR
- Direct AMPK activator
- Glucose uptake, fatty acid oxidation
- Phase 1 human trials (discontinued)
- Oral or injectable
- First-generation exercise mimetic. Poor oral bioavailability and cardiac side effects halted development
- GW501516 (Cardarine)
- PPAR-delta agonist
- Increased fat oxidation, endurance capacity
- Preclinical (withdrawn from development)
- Oral
- Withdrawn after carcinogenicity findings in rodent studies. REV-ERB modulators don't share this pathway
- Metformin
- AMPK activator (indirect via complex I inhibition)
- Reduced hepatic glucose output, improved insulin sensitivity
- FDA-approved, extensive human data
- Established diabetes treatment. Weaker exercise-mimetic effects than SLU-PP-332 but decades of safety data
- Resveratrol
- SIRT1 activator, mild AMPK activation
- Mitochondrial biogenesis, anti-inflammatory
- Human trials show minimal metabolic effects at achievable doses
- Popular supplement with poor bioavailability. Effects seen in vitro don't translate at oral doses humans can tolerate
- SLU-PP-332 sits between first-generation exercise mimetics (AICAR, GW501516) that were abandoned due to toxicity or inefficacy and established metabolic drugs (metformin) that produce modest AMPK activation as a secondary effect. The REV-ERB pathway offers theoretical advantages: more selective metabolic targeting than PPAR agonists, better bioavailability than AICAR, and a mechanism of action distinct from compounds that failed due to off-target cardiac or oncogenic effects. The limiting factor remains absence of human pharmacokinetic data, long-term safety profiles, and Phase 1 dose-escalation studies that would establish therapeutic windows.